INVESTIGATIONAL TECHNOLOGY PLATFORM

CELLULARSCIENCE FOR HEALTHSPAN RESEARCH

SCROLL TO EXPAND

Our MissionDeveloping investigational cellular technology for responsible healthspan research

Celljevity is developing investigational cellular technology, biomarker analysis tools, and research infrastructure for responsible longevity science.

A future where cellular aging biology is better understood through rigorous research, qualified medical governance, and transparent communication.

Learn More

Research Context

Documented development controls
XPRIZE Logo
Healthspan Semi-Finalist
UCLA Logo
Research Partnership
Nature Journal Logo
Scientific literature context
Documented development controls
XPRIZE Logo
Healthspan Semi-Finalist
UCLA Logo
Research Partnership
Nature Journal Logo
Scientific literature context

The Prometheus PlatformIn Development

Our investigational platform combines cellular science, biomarker analysis, and software infrastructure for responsible healthspan research.

Cellular Research

Study autologous cells and cellular-aging-associated markers through a proprietary research platform.

Biomarker Analysis

Organize cellular and biomarker data for qualified scientific and medical review.

Defined Workflow

Protocol timelines depend on provider assessment, laboratory workflow, and local requirements.

Research Applications

Exploratory work across cellular aging biology, inflammation pathways, tissue repair, and longitudinal biomarkers.

Research Workflow

The Investigational Workflow

From inquiry to laboratory and provider review in defined steps.

1

Tissue Collection

Where appropriate, sample collection is performed by licensed providers under applicable requirements

2

Cell Isolation

Fibroblasts may be isolated and expanded under controlled laboratory processes

3

Laboratory Protocol

A proprietary process is being studied for cellular-aging-associated markers

4

Quality Validation

Single-cell RNA sequencing may support cell-state characterization and quality review

5

Provider Review

Any clinical use is subject to licensed provider judgment and local regulation

6

Results & Monitoring

Biomarker and cellular data may be reviewed over time under applicable protocols

Timelines vary by provider assessment, protocol, laboratory workflow, and jurisdiction.

Learn More

The Science Behind Prometheus

Research Areas Under Review

Prometheus is an investigational platform studying autologous cells, epigenetic reprogramming, and biomarker analysis in cellular aging biology.

Public research references and publication counts should be reviewed with scientific and legal advisors before being used as substantiation.

Senolytics

Senescent cells are an active area of aging research. Celljevity reviews this biology as part of its investigational platform development.

Epigenetics

Epigenetic patterns are studied as markers of cellular state and aging biology within controlled research workflows.

Metabolism

Mitochondrial and metabolic markers may help characterize cell state in research settings.

Immunology

Immune and inflammatory signaling are reviewed as research areas, without implying clinical efficacy.

Clinical Collaboration Network

Provider-Led Collaboration

Celljevity coordinates research and technology collaborations. Any medical assessment, procedure, or follow-up is conducted by licensed providers where legally permitted.

Clinique DelMar Antibes

Antibes, France

Clinique DelMar

Potential collaboration in France is subject to licensed provider oversight, local governance, and applicable regulatory review.

Provider-led review
FLCHUAE

Under Evaluation

Global Expansion

Future regional collaborations are under evaluation and are not presented as operational treatment sites.

Prometheus Technology

Review Considerations (Educational Only)

Prometheus is an investigational cellular technology platform. This website does not determine eligibility or offer treatment.

Any clinical activity requires independent medical review, informed consent, and jurisdiction-specific legal and regulatory assessment.

Criteria & Screening

Provider-Led Eligibility Review

Suitability cannot be determined from website content. Any clinical activity requires independent medical judgment and local regulatory review.

Global clinic network and patient presence

Criteria & Screening:

18+

Adult inquiries only

Review

Protocol-specific criteria

Required

Independent provider assessment required

Protocol Considerations:

Adult status and informed-consent capacity

Independent review of medical history

Protocol-specific inclusion criteria

Protocol-specific exclusion criteria

Jurisdiction-specific legal and ethics review

Licensed provider determination

Eligibility depends on protocol-specific criteria and licensed provider review.

Learn About Eligibility

Request educational information about research context and provider-led review requirements.

Our Team

World-Class Leadership

Led by experienced executives and guided by distinguished advisors

Leadership Team

Diederik van der Reijt

Chief Executive Officer

Paris, France

LinkedIn

Serial biotech entrepreneur and investor founded Celljevity and co-founded NKore Biotherapeutics. Leveraging his background in trading and venture capital, he works to scale science-backed biotechnology platforms responsibly.

Dr. Henk Viëtor

Chief Medical Officer

Amsterdam, Netherlands

LinkedIn

Co-founded and led more than 20 life sciences companies, including Drug Discovery Factory, Skyline Diagnostics, Julius Clinical, DC4U, MyLife Technologies, and Oncodrone. Physician, scientist, and serial biotech entrepreneur with expertise in clinical immunology, transfusion medicine, and genetics.

Dr. Heshan "Grasshopper" Illangkoon PhD

Chief Innovation Officer

Florida, USA

LinkedIn

Biomedical engineer and translational scientist focused on responsible longevity research and cellular technology development. Leads Celljevity's innovation pipeline, bridging AI-driven discovery, clinical partners, and global research networks.

Dr. Digvijay Gahtory

Chief Business Officer

Amsterdam, Netherlands

LinkedIn

Has over 8 years of experience in strategy consulting and entrepreneurship. Has raised more than €100 million in financing for life science companies. Founder and CEO of Bimini Biotech.

Karen Brink

Chief Growth Officer

Oxford, England

LinkedIn

Focuses on growth strategies and thought leadership. Skilled and experienced investor who has founded several healthcare companies. Holds a Blockchain Strategy degree from Oxford.

Rhys Tombling

Finance Director

London, England

Has 10 years of experience in the private sector, specializing in financial control & operations for start-ups and scale-ups in FMCG and SaaS. Holds an ACA-ICAEW accountancy qualification and a BA in Accountancy and Finance from Newcastle University.

Daniel Erasmus

Chief Artificial Intelligence Architect

Brussels, Belgium

LinkedIn

Medical & Scientific Board

Dr. Yi Eve Sun

Chief Science Officer

Shanghai, China

LinkedIn

Professor, UCLA Department of Molecular & Medical Pharmacology. Pioneer in neural stem cell biology and leading expert in cellular reprogramming. Academic excellence with breakthrough discoveries in JAK-STAT pathways and successful translation from bench to bedside.

Dr. Henry Delmar

Founder, Clinic Del Mar

Nice, France

Member of the European Board of Plastic Surgeons (EBOPRAS), specializes in Plastic, Reconstructive, and Aesthetic Surgery. President of the French Society of Aesthetic Plastic Surgery (SOFCEP) and member of IPRAS and ESPRAS.

Dr. Christopher Juel-Jensen

Chief Integration Officer

London, England

LinkedIn

Surgeon, investment banker, and leader in healthcare and longevity science. Combines finance and medicine, previously working at J.P. Morgan, Goldman Sachs, Deutsche Bank, and Swiss Bank Corp., now developing healthcare and wellness platforms worldwide.

Dr. Pierre Maldiney

Cardiologist & Anti-Aging Physician

Paris, France

Cardiologist, morphologist, and anti-aging physician with training in nutritional and functional medicine with Professor Vincent Castronovo. President of AEM2F, the European Association of Mitronutrition and Functional Medicine.

Dr. Lin Quan

Clinical Director, UCLA

Los Angeles, USA

Clinical Director for preclinical research, focusing on Auto-rFib therapy research with expertise in cell culture and animal experiments. Leads preclinical investigations for neurodegenerative disease applications.

Doris Rathgeber

Medical Director, Body & Soul

Shanghai, China

LinkedIn

Founder and Medical Director of Body & Soul in Shanghai. With over 20 years' experience in Traditional Chinese and Western Medicine, specializes in women's health, fertility, and pediatrics, delivering care in four languages.

Dr. Murat Bozkurt

Medical Advisor

Ankara, Turkey

Advisory Board

Paul Spiegel

Strategic Advisor

Tokyo, Japan

LinkedIn

International business development executive with extensive experience in Asia-Pacific markets and cross-border partnerships. Specializes in strategic planning and market expansion for biotechnology companies, with deep expertise in regulatory affairs and commercial strategy.

Neil Bush

Senior Advisor

Houston, USA

Global business leader with 40+ years experience specializing in cross-border investments in Asia and the Middle East. Founder of the George H. W. Bush Foundation for U.S.-China Relations. Chairs Points of Light and the Bush School Advisory Board.

Anne Popkin

Strategic Advisor

USA

LinkedIn

Senior executive and strategic advisor with extensive experience in finance, biotechnology, and investor advocacy. Recognized for leadership roles at major asset management firms and commitment to advancing women's representation in finance. Active philanthropist supporting education, science, and ocean preservation.

Stephen Bradley

Non-Executive Director

Hong Kong

LinkedIn

Former British Consul-General to Hong Kong, graduated from Oxford in 1980 and studied at Fudan University. Leverages extensive diplomatic experience across Asia to advise on cross-border consultancy and strategic development. Serves on the boards of Cenovus Energy Inc., CK Asset Holdings, and Power Assets Holdings.

David Bizer

Investment Advisor

Singapore

LinkedIn

Co-founder and Managing Partner of GCW Global Customised Wealth, specializing in private equity and family office investments. Previously held senior positions at Jasper Ridge Partners, Nomura, and Lehman Brothers. Has served as an economic advisor to two U.S. Presidents. Ph.D. in Economics from Stanford University.

Rachid Bouzouba

Co-Founder, MCM Partners

Hong Kong

Co-Founder and Chairman of MCM Partners, a Hong Kong-based merchant bank and corporate advisory firm. Accomplished finance executive with extensive leadership in global equities and derivatives, previously serving as Head of Global Equities at Nomura and Head of European Equities at Lehman Brothers.

Shirin Azad

Strategic Advisor

Europe

Questions & Answers

Frequently Asked Questions

Educational information about Prometheus technology

Can't find what you're looking for? Contact our team

Treatment Process

Clinical & Scientific

Still have questions? Contact our specialist team

Contact Us

Important notice: Celljevity is a biotechnology company developing investigational cellular technology. Information on this website is educational only and is not medical advice, a treatment recommendation, or an offer to provide medical services. Celljevity technology is not approved by the FDA or EMA. Any clinical activity is subject to independent medical review, local regulation, and licensed provider oversight.